Compulsory Licensing
DavidLegge (Talk | contribs) |
DavidLegge (Talk | contribs) |
||
| (One intermediate revision by one user not shown) | |||
| Line 32: | Line 32: | ||
November 2006, Oxfam Briefing paper: Five years ago, members of the World Trade Organisation (WTO) signed a ministerial agreement to ensure that intellectual property rules would no longer obstruct developing countries’ efforts to protect public health. Since then, however, little has changed. Patented medicines continue to be priced out of reach for the world’s poorest people. Trade rules remain a major barrier to accessing affordable versions of patented medicines (generic medicines). The prevalence of debilitating and life-threatening diseases in poor countries is growing, but medicines are simply not available. Urgent action is needed. <br /> | November 2006, Oxfam Briefing paper: Five years ago, members of the World Trade Organisation (WTO) signed a ministerial agreement to ensure that intellectual property rules would no longer obstruct developing countries’ efforts to protect public health. Since then, however, little has changed. Patented medicines continue to be priced out of reach for the world’s poorest people. Trade rules remain a major barrier to accessing affordable versions of patented medicines (generic medicines). The prevalence of debilitating and life-threatening diseases in poor countries is growing, but medicines are simply not available. Urgent action is needed. <br /> | ||
http://www.oxfam.org.uk/what_we_do/issues/health/bp95_patents.htm | http://www.oxfam.org.uk/what_we_do/issues/health/bp95_patents.htm | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Return to [[Intellectual Property and Pharmaceuticals | IP Resources page]] | Return to [[Intellectual Property and Pharmaceuticals | IP Resources page]] | ||
| + | </br> | ||
| + | [[PHM_Oz_IP_Project|IP Project Page]] | ||
Latest revision as of 00:00, 11 July 2007
WTO documents give a good overview of compulsory licensing and the key dates and documents: Fact Sheet Sept 2006 PDF file
Technical Note on pharmaceutical patents and the TRIPS agreement Web link
MSF documents are quite illuminating in how this fits into practical usage: PDF file, Web link
Report of WHO Commission on Intellectual Property Rights, Innovation and Public Health
Web link
Legal Framework for Compulsory License Drugs, Knowledge Ecology International, 16 March 2007 PDF file
WHO Presses Development of Cheap Drugs
May 23, 2007: [BRADLEY S. KLAPPER, Associated Press] The U.N. health agency approved a resolution Wednesday urging experts to find new ways of financing medicine and vaccine development to lower drug prices and improve worldwide availability.
Access full article
WHO’s mandate on IPRs under US attack
12 Dec 2006: At the recent meeting of WHO’s international working group on public health, innovation and intellectual property, the US challenged WHO’s work on the impact of Intellectual Property Rights (IPRs).
Read full article here
All costs, no benefits: How TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines
March 2007, Oxfam Briefing paper: The USA continues to impose TRIPS-plus rules on developing countries, thus preventing poor people from accessing inexpensive, generic medicines. Jordan was required under the terms of its WTO accession package and its free trade agreement (FTA) with the USA to introduce TRIPS-plus rules. Medicine prices have increased drastically, and TRIPS-plus rules were partly responsible for this increase.
http://www.oxfam.org/en/policy/briefingpapers/bp102_jordan_us_fta
Patents versus Patients: Five years after the Doha Declaration
November 2006, Oxfam Briefing paper: Five years ago, members of the World Trade Organisation (WTO) signed a ministerial agreement to ensure that intellectual property rules would no longer obstruct developing countries’ efforts to protect public health. Since then, however, little has changed. Patented medicines continue to be priced out of reach for the world’s poorest people. Trade rules remain a major barrier to accessing affordable versions of patented medicines (generic medicines). The prevalence of debilitating and life-threatening diseases in poor countries is growing, but medicines are simply not available. Urgent action is needed.
http://www.oxfam.org.uk/what_we_do/issues/health/bp95_patents.htm
Return to IP Resources page
</br>
IP Project Page
